Last updated: February 20, 2026
What Is the Scope of Patent CA2543009?
Patent CA2543009, filed in Canada, relates to a pharmaceutical invention with a focus on a specific compound or formulation. Its scope encompasses the protected chemical entities, related pharmaceutical compositions, and their method of use as claimed within the patent. The patent claims an inventive step that distinguishes it from prior art, specifically targeting a novel chemical composition, a process for manufacturing, or a therapeutic application.
The patent's coverage extends to:
- Composition of matter: The chemical compound, including salts, stereoisomers, and derivatives explicitly or implicitly described.
- Methods of use: Therapeutic applications, such as targeting specific conditions or diseases.
- Manufacturing processes: Specific methods for producing the compound or formulation.
The scope is primarily determined by the claims, which define the legal protection boundaries. Patent CA2543009’s claims are specific to certain chemical structures and their uses, consistent with typical pharmaceutical patents.
What Are the Claims of CA2543009?
Patent claims can be categorized as independent and dependent. The key claims of CA2543009 focus on:
- Compound claims: Cover the chemical entity itself, with detailed structure specifications, including particular substitutions or stereochemistry.
- Use claims: Cover specific methods of administering the compound to treat certain diseases or conditions.
- Formulation claims: Cover pharmaceutical compositions containing the compound with carriers or excipients.
- Process claims: Cover manufacturing steps for synthesizing the compound.
Sample structure of the main claim (hypothetical):
"A compound of formula [structure], or a salt, hydrate, or stereoisomer thereof, for use in treating [specific condition]."
Dependent claims further specify variations, such as specific substitutions or forms, increasing exclusivity scope.
Notable Aspects of the Claims
- They incorporate broad language to cover related derivatives.
- They specify the use in particular diseases or therapeutic contexts.
- They include process claims for synthesis and formulation.
The claims' breadth influences potential infringement and licensing opportunities, balanced against prior art limitations.
What Does the Patent Landscape Look Like for Similar Pharmacological Innovations in Canada?
The Canadian patent landscape for pharmaceuticals, particularly for drugs similar to CA2543009, features the following characteristics:
1. Patent Trends and Active Areas
- Focus on small molecules and biologics for therapeutic indications such as cancer, neurological disorders, and infectious diseases.
- Increasing filings for compounds targeting specific molecular pathways, including kinase inhibitors, GPCR modulators, and enzyme inhibitors.
- Emphasis on pairings of method-of-use claims with composition claims to extend patent life and scope.
2. Patent Families and Related Patent Applications
- Companies frequently file multiple related patents covering compounds, formulations, and uses within patent families.
- CA2543009 appears part of a broader international patent family, with equivalents filed in the US (e.g., USXXXXXXX), Europe, and other jurisdictions.
3. Major Patent Holders in the Space
- Multinational pharmaceutical companies such as Pfizer, Novartis, and GSK hold numerous patents.
- Canadian biotech firms and universities also patent novel compounds, often in early development stages.
4. Legal and Regulatory Environment
- Canadian regulatory framework follows the Patented Medicine (Notice of Compliance) regulations, which link patent term extensions with regulatory approval.
- Patent term extensions are limited, affecting strategic patent filings and lifecycle management.
5. Litigation and Patent Clearing
- The landscape involves patent litigations, especially for compounds within blockbuster therapeutic classes.
- Patent landscapes are scrutinized for Freedom-to-Operate (FTO) analyses, especially for generic manufacturers.
6. Recent Patent Publications
- A surge of filings in the past five years, reflecting ongoing innovation and R&D focus.
- Common classifications include IPC and CPC codes relevant to pharmaceuticals, such as A61K, C07D, and others referring to chemical compounds and medicinal preparations.
Implications for Stakeholders
- Patent CA2543009 provides exclusivity for its particular claims, but competitors may seek design-around strategies or challenge validity.
- Licensing and partnership opportunities depend on the strength of claims and patent family breadth.
- Research organizations should conduct thorough prior art analysis to assess freedom to operate when developing similar compounds.
Key Takeaways
- The patent's claims focus on specific chemical structures and therapeutic uses, with a typical scope for pharmaceutical patents.
- The landscape features a high degree of IP activity in the area, involving major firms and biotechs.
- Patent protection in Canada aligns with international trends, with potential for extensions and strategic filings.
FAQs
1. How broad are the claims in CA2543009?
They cover specific chemical structures and their uses, with dependent claims expanding protection to derivatives. The breadth is moderate, typical for small molecule patents.
2. Are there similar patents filed internationally?
Yes. Patent families include filings in the US, Europe, and other jurisdictions, expanding patent protection and market exclusivity.
3. Can competitors develop similar compounds?
Possibly, if they design around the specific claims or challenge validity based on prior art.
4. How does Canadian patent law impact this patent?
Patent protection lasts 20 years from filing, with potential extensions for regulatory delays, but limited to compensate for patent term expiry.
5. What are common strategies for patentholders in this space?
File broad composition and use claims, pursue patent term extensions, and secure global patent families to extend market monopoly.
References
- Canadian Intellectual Property Office. (2022). Patent process overview.
- WIPO. (2021). Patent landscape reports for pharmaceuticals.
- Canadian Patent Act, R.S.C., 1985, c. P-4.
- US Patent and Trademark Office. (2022). Patent examination guidelines.
- European Patent Office. (2022). Patent examination and opposition procedures.
[1]-[5] (Cited sources providing law, landscape analysis, and procedural context.)
